Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. on February 8, 2018. The registrant is an emerging growth company incorporated in Delaware. The report details a material definitive agreement entered into on the filing date regarding a public offering of securities.
Key Financial Metrics and Transaction Details
The filing describes a firm commitment underwritten public offering with the following structure:
- Securities Offered: 5,707,500 shares of Common Stock, 2,942,500 Pre-Funded Warrants, and Preferred Stock Warrants to purchase up to 865,000 shares of Series A Convertible Preferred Stock.
- Offering Price: $1.01 per share of Common Stock or $1.00 per Pre-Funded Warrant, each sold with an accompanying Preferred Stock Warrant.
- Expected Net Proceeds: Approximately $7.5 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Funding clinical and preclinical program development, research and development activities, capital expenditures, and working capital needs.
- Underwriter Compensation: H.C. Wainwright & Co., LLC received a 7.0% underwriting commission, a 1.0% management fee, and warrants to purchase 432,500 shares of Series A Preferred Stock (or 497,375 if the option is fully exercised).
The filing does not provide historical revenue, profit, cash flow, or debt metrics as this is a current report focused on a specific transaction rather than a periodic financial statement.
Material Changes and Corporate Actions
The primary material change is the entry into the Underwriting Agreement and the creation of a new class of equity:
- Series A Convertible Preferred Stock: The Company filed a Certificate of Designation for Series A Convertible Preferred Stock. Each 0.1 share converts into one share of Common Stock.
- Charter Amendment Requirement: The Company currently lacks sufficient authorized Common Stock to cover conversions. A Charter Amendment must be approved by stockholders before the Series A Preferred Stock can be converted.
- Lock-Up Period: The Company agreed not to offer, issue, or sell Common Stock or convertible securities for 135 days following the Offering without the Underwriter's consent.
- Over-Allotment Option: The Underwriter holds a 30-day option to purchase up to 1,297,500 additional shares of Common Stock and/or related warrants.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The Offering is expected to close on or about February 12, 2018. Management intends to use proceeds to advance clinical programs, specifically referencing the INSPIRE Pivotal phase 3 trial for rigosertib.
Risks and Contingencies:
- Financing Needs: The filing explicitly states the Company may need to scale back operations if adequate financing is not obtained in the future.
- Conversion Restrictions: Holders are prohibited from converting Series A Preferred Stock if the conversion would result in ownership exceeding 4.99% (or 9.99% in certain circumstances) of outstanding Common Stock.
- Warrant Expiration: Preferred Stock Warrants expire on the later of one year after the Charter Amendment filing or the earlier of one month after the release of top-line results for the INSPIRE trial or December 31, 2019.
- Forward-Looking Statements: The report includes standard disclaimers regarding risks related to clinical trial success, regulatory approval, and market conditions.
Investor Verification Checklist
- Verify the closing date of the Offering (expected February 12, 2018) and the actual net proceeds received.
- Confirm the status of the Charter Amendment required to authorize sufficient Common Stock for Series A conversion.
- Monitor the timeline for the release of top-line results for the INSPIRE Pivotal phase 3 trial, as this impacts warrant expiration.
- Review the full text of the Underwriting Agreement and Certificate of Designation (Exhibits 1.1 and 3.1) for specific terms regarding anti-dilution adjustments and voting rights.
- Assess the Company's cash runway post-offering to determine the likelihood of needing additional financing or scaling back operations.